TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07205159: A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.

Sponsor: Forte Biosciences, Inc. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,298,264

Rescue Site Savings

+$1,508,784

Unlock Full NCT07205159 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07205159 Rescue Dossier →